Early and late extensive chronic graft-versus-host disease in children is characterized by different th1/th2 cytokine profiles: Findings of the children's oncology group study ASCT0031

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 12, 2011, Pages 1804-1813

  Rozmus, Jacob ^a   Schultz, Kirk R ^a,b   Wynne, Kristin ^a   Kariminia, Amina ^a   Satyanarayana, Preeti ^c   Krailo, Mark ^d   Grupp, Stephan A ^e   Gilman, Andrew L ^f   Goldman, Frederick D ^g  

^a BC CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Sacred Heart HealthCare System   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Levine Children's Hospital   (United States)

^g CHILDREN S HOSPITAL OF ALABAMA   (United States)

Author keywords

Biomarker; Blood and marrow transplantation

Indexed keywords

CD3 ANTIBODY; CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; IONOMYCIN; MESSENGER RNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHORBOL 13 ACETATE 12 MYRISTATE; PLACEBO; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; TH1 CELL; TH2 CELL;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; GRAFT VS HOST DISEASE; HUMANS; HYDROXYCHLOROQUINE; INFANT; INTERFERON-GAMMA; INTERLEUKINS; MALE; RNA, MESSENGER; TH1 CELLS; TH2 CELLS; YOUNG ADULT;

EID: 81255158931     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.05.011     Document Type: Article

References (57)

1. Mehta P., Locatelli F., Stary J., et al. Bone marrow transplantation for inherited bone marrow failure syndromes. Pediatr Clin North Am 2010, 57:147-170.
2. Gaziev J., Sodani P., Lucarelli G. Hematopoietic stem cell transplantation in thalassemia. Bone Marrow Transplant 2008, 42(Suppl 1):S41. (Review).
3. Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant 2008, 42(Suppl 1):S49-S52.
4. Sullivan K.M., Muraro P., Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant 2010, 16(1 Suppl):S48-S56.
5. Prasad V.K., Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. Br J Haematol 2010, 148:356-372.
6. Przepiorka D., Anderlini P., Saliba R., et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001, 98:1695-1700.
7. Fraser C., Bhatia S., Ness K., et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 2006, 108:2867-2873.
8. Arora M., Burns L.J., Davies S.M., et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 2003, 9:38-45.
9. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007, 110:3784-3792.
10. Fujii H., Cuvelier G., She K., et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008, 111:3276-3285.
11. Schultz K.R., Paquet J., Bader S., et al. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995, 16:289-295.
12. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
13. Wechalekar A., Cranfield T., Sinclair D., et al. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol 2005, 27:247-249.
14. Patriarca F., Skert C., Sperotto A., et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006, 34:389-396.
15. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007, 13:6107-6114.
16. Cousineau S., Belanger R., Perreault C. Characterization of plasma cell populations at autopsy after human allogeneic bone marrow transplantation. Am J Pathol 1986, 124:74-81.
17. + B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008, 14:208-219.
18. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9:505-511.
19. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host diease. Blood 2006, 108:756-762.
20. Zaja F., Bacigalupo A., Patriarca F., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007, 40:273-277.
21. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
22. Hoffmann P., Ermann J., Edinger M., et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196:389-399.
23. Young K.J., DuTemple B., Phillips M.J., et al. Inhibition of graft-versus-host disease by double-negative regulatory T cells. J Immunol 2003, 171:134-141.
24. Miura Y., Thoburn C.J., Bright E.C., et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004, 104:2187-2193.
25. + regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005, 106:2903-2911.
26. high regulatory T cells. Blood 2004, 103:2410-2416.
27. high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp Hematol 2005, 33:894-900.
28. + effector memory cells relative to central memory cells. Blood 2004, 103:3986-3988.
29. low subset. Eur J Immunol 2004, 34:408-417.
30. Biedermann B.C., Sahner S., Gregor M., et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002, 359:2078-2083.
31. Patey-Mariaud de Serre N., Reijasse D., Verkarre V., et al. Chronic intestinal graft-versus-host disease: clinical, histological and immunohistochemical analysis of 17 children. Bone Marrow Transplant 2002, 29:223-230.
32. +) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood 2001, 98:3162-3164.
33. Ritchie D., Seconi J., Wood C., et al. Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:706-712.
34. Ochs L.A., Blazar B.R., Roy J., et al. Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant 1996, 17:1085-1092.
35. Bogunia-Kubik K., Mlynarczewska A., Wysoczanska B., et al. Recipient interferon-gamma 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 2005, 90:425-426.
36. Baker J., Verneris M.R., Ito M., et al. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001, 97:2923-2931.
37. Haraguchi K., Takahashi T., Matsumoto A., et al. Host-residual invariant NK T cells attenuate graft-versus-host immunity. J Immunol 2005, 175:1320-1328.
38. Pashankar F., Singhal V., Akabogu I., et al. Intact T cell responses in ataxia telangiectasia. Clin Immunol 2006, 120:156-162.
39. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
40. Kinet S., Bernard F., Mongellaz C., et al. gp120-mediated induction of the MAPK cascade is dependent on the activation state of CD4(+) lymphocytes. Blood 2002, 100:2546-2553.
41. Rivas M.N., Hazzan M., Weatherly K., et al. NK cell regulation of CD4 T cell-mediated graft-versus-host disease. J Immunol 2010, 184:6790-6798.
42. Larghero J., Rocha V., Porcher A., et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA-identical sibling bone marrow transplants. Br J Haematol 2007, 138:101-109.
43. Olson J.A., Leveson-Gower D.B., Gill S., et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effect. Blood 2010, 115:4293-4301.
44. Lund F.E., Randall T.D. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010, 10:236-247.
45. Cote-Sierra J., Foucras G., Guo L., et al. Interleukin-2 plays a central role in Th2 differentiation. Proc Natl Acad Sci U S A 2004, 101:3880-3885.
46. Malek T.R. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003, 74:961-965.
47. Wrenshall L.E., Smith D.R., Stevens E.T., et al. Influence of interleukin-2 deficiency on the generation of autoimmune B cells. J Autoimmun 2007, 29:125-133.
48. Willerford D.M., Chen J., Ferry J., et al. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 2005, 3:521-530.
49. She K., Gilman A.L., Aslanian S., et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:386-397.
50. D'Orsogna L.J., Wright M.P., Krueger R.G., et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells. Biol Blood Marrow Transplant 2009, 15:795-803.
51. + T cells. Eur J Immunol 2007, 37:129-138.
52. Broady R., Yu J., Levings M.K. ATG-induced expression of FOXP3 in human CD4(+)T cells in vitro is associated with T-cell activation and not the induction of FOXP3(+) T regulatory cells. Blood 2009, 114:5003-5006.
53. + CD8 T cells (T(EMRA)) in chronic graft-versus-host-disease. Leukemia 2006, 20:545-547.
54. James E., Chai J.G., Dewchand H., et al. Multiparity induces priming to male-specific minor histocompatiblity antigen, HY, in mice and humans. Blood 2003, 102:388-393.
55. He B., Qiao X., Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 2004, 173:4479-4491.
56. Zecca M., Prete A., Rondelli R., et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002, 100:1192-1200.
57. Puzik A., Schultz C., Iblher P., et al. Effects of ciclosporin A, tacrolimus and sirolimus on cytokine production in neonatal immune cells. Acta Paediatr 2007, 96:1483-1489.